MSD Animal Health has announced the launch of Cepralock, a new teat sealant to complement its dry cow intramammary product Cepravin Dry Cow and wider Dairy Herd Health portfolio.
The company says the new product is designed for use at drying off, with or without a dry cow intramammary antibiotic, and provides an important inert barrier in the teat canal to reduce significantly the risk of bacterial infection of the udder during the dry period.
Cepralock is supplied in tubes with the option of short nozzles that are designed to help avoid the risk of teat damage and incorrect administration beyond the teat canal.
The launch is also being accompanied by dry cow therapy training and a support programme for veterinary practitioners and their dairy farmer clients. This will include diagnostics and data analytics, and training will have a significant focus on correct administration and removal of teat sealant after calving, allowing vets to provide adequate reassurances to their clients around product use.
MSD Animal Health technical adviser Martin Behr said: "The dry period is a critical time for vets as they seek to help their clients in the battle to combat mastitis, which remains a significant drain on dairy herd profitability. It provides an ideal opportunity to clear up existing bacterial infections in the udder with the use of intramammary antibiotics, but it is also vital to prevent new infections over the period.
"Cows do have their own natural physical defence against infection in the form of the keratin plug that forms in the teat canal after drying off, but this is not always sufficiently effective. In a recent study it was shown that only 50% of 500 examined quarters had a fully developed keratin plug within 10 days of drying off, whilst 20% of teats remained open into the second half of the dry period. This is significant because the majority of clinical cases of mastitis that occur during the dry period do so within the first three weeks.
"Correct use of a teat sealant at drying off, immediately after the administration of the dry cow intramammary if used, will provide an effective physical barrier for the duration of the dry period, significantly reducing the chances of new infections of the udder."
According to MSD, it is estimated that less than half of dairy cows are currently given a teat sealant at drying off, despite the concept being established for a number of years and numerous farm studies providing strong evidence of their efficacy.
Martin added: "The potential return on investment for dairy farmers of correctly applied teat sealants is clear. A single case of mastitis is estimated to cost between £70 and £250 and the average UK dairy herd suffers somewhere in the region of 50 to 60 cases per 100 cows per lactation. A correctly applied dry cow therapy programme, including the use of teat sealants, will significantly reduce the incidence of clinical mastitis, thereby providing a demonstrable return on investment.
"At MSD Animal Health we are keen to help veterinary practitioners promote best practice in dry cow therapy, including the adoption of the correct protocols and application procedures. Therefore we are supporting the launch of Cepralock with the offer of Continuous Professional Development for veterinary practitioners on all aspects of dry cow therapy, including correct use of teat sealant and its removal after calving."
Cepralock teat sealant is available to veterinary practices in packs of 24 tubes and 120 tubes.
For more information about Cepralock or MSD's Dry Cow Management Support package for vets and farmers, contact your Account Manager.
Prior to joining Fitzpatrick Referrals, Gerard was a Senior Lecturer in Internal Medicine at the University of Glasgow as well as Head of the Emergency Service and Director of both the Internship and ECVIM Residency Programmes. He is also a European and Royal College Recognised Specialist in Internal Medicine, and recently became one of few specialists in the world to have completed a 12 month Fellowship in Interventional Radiology at the Animal Medical Center in New York.
Gerard said: "When I returned to the UK, it was a natural fit for me to join Fitzpatrick Referrals. The team all share the same ethos and together I know we will be able to offer a truly world-class service to our patients and their family. I genuinely believe we will be able to change what is accepted as the gold standard of care for animals in the UK."
Fitzpatrick Referrals says its interventional radiology service performs minimally invasive procedures that are often considered the standard of care in human medicine, providing options for veterinary patients where conventional therapies are not associated with the best outcome.
Clinical Director of Oncology and Soft Tissue, Professor Nick Bacon said: "Gerard joining the team in Guildford opens new doors for our patients but more importantly we hope the disciplines of veterinary oncology and soft tissue surgery as a whole. He brings huge experience in interventional radiology solutions for portosystemic shunts, tracheal collapse and urinary calculi obstruction. Gerard is also key to developing our cancer care. Progress is not about ever bigger treatments chasing a cure; it can just as easily mean delivering palliative or curative-intent treatments in smarter ways, with less side-effects and lower morbidity. I am looking forward to watching our treatments evolve for a variety of tumours including urinary, liver, lung and head and neck. No cancer treatment is perfect, but we are striving for the best we can for the patient in front of us."
Noel Fitzpatrick said: "It remains my objective to build the greatest team of super-specialists on planet earth where we can offer all of the options to all of the animals and the families that love them all of the time. Gerard has a unique skill set that will not only complement our growing team, but will enhance the spectrum of treatments we can offer and which the families of animals throughout the UK and beyond really want. Increasingly people want the same level of care for their dogs and cats as we have for ourselves and our goal is to deliver exactly that with the very best team and facilities in the world today."
Fitzpatrick Referrals will be holding a Partners in Care CPD session on 25th May inviting vets to meet Dr Gerard McLauchlan and discover more about the interventional radiology service. To register your interest, contact Sarah on SarahC@fitzpatrickreferrals.co.uk.
Representatives from all sectors of the veterinary profession are encouraged to apply for the role, which is to represent veterinary surgeons in those regions to BVA Council and help shape the association's strategy and policy development.
Candidates are required to be based in the region they represent and to have time available to commit to gathering members’ views on key policy areas, representing those views at three meetings per year in London, and one elsewhere in the UK (attached to BVA Members’ Day). They will also need to meet members at local events where possible, and promote the good name and values of BVA. All of this work is supported by BVA headquarters.
The term of the BVA regional representative role is for three years. It suits motivated individuals who are interested in current issues affecting the profession. BVA pays your expenses and you’ll get free BVA membership for the duration of your term.
Daniella Dos Santos, President of the British Veterinary Association (pictured right), said: "BVA Council plays a key role in helping us to achieve our mission as the leading body representing, supporting and championing the whole UK veterinary profession. Our regional representatives are integral to that mission and to the activities of Council - contributing to effective horizon scanning on matters of veterinary policy and providing an informed steer to BVA’s Policy Committee.
"With an increasingly complex veterinary landscape, and wide range of issues and potential outcomes for animal health and welfare and the veterinary profession it’s essential that members have the best person to represent them at the highest level within BVA."
Emma Callaghan, BVA Scottish Branch regional representative and 2019 Bleby Cup winner, added: "I am currently in the middle of my first term on BVA Council and I would encourage anyone who is considering taking part to put themselves forward for election. This is a fantastic chance to represent the views of your region and to help BVA members to get their voices heard. I’m really enjoying my time as a regional representative - it’s been such a wonderful opportunity to meet a range of people from across the profession and to develop new skills outside my day-to-day role."
BVA members who are interested in becoming a representative for their area can apply before 9am on 16 December 2019 when nominations close. For more information or to submit your application, visit www.bva.co.uk/council/
Sarah Gasper, BEVA’S Learning Manager said: "Many of us on the BEVA education team understand exactly what it’s like to return to practice whether after a career break, paternity/maternity or sickness leave. We also understand the specific challenges of moving from mixed into equine practice.
"We have created these courses to help make the transition back to work as smooth as possible. We’ve tried to incorporate everything we wish we had had access to when we returned to practice!"
Reinvigorate your approach to equine practice will be held on 12th March 2019 at Lythe Hill Hotel, Haslemere. The lecture and forum based course will explore the latest advances in internal medicine, orthopaedics, and sports medicine, and how to apply them to develop evidence-based clinical approaches to common and emergency scenarios in practice.
Getting (back) into equine practice will be held on 13th March 2019 at Liphook Equine Hospital, Hampshire. This entirely practical day of CPD will all be about improving the confidence of established equine vets and for vets returning to work following a career break. The course will focus on the practical procedures that an established equine ambulatory vet might be expected to perform on a regular basis. In a new approach to CPD we are trialling a system where delegates can shape part of this unique CPD day for themselves, with an online poll pre-course to select from a choice of practicals.
Both courses will have childcare facilities to help support parents wishing to attend CPD.
BEVA will also be running a course on the fundamentals of sedation, field anaesthesia and castration on 27th and 28th March 2019 at World Horse Welfare, Snetterton, Norfolk. This 'hands-on' course is designed for new or recent graduates or those in mixed practice with varied levels of equine work. It comprises evening lectures on the first day to free up more time for hands-on training on day two. It will cover sedation and field anaesthesia required for common field surgery such as castration, both in theory and in a practical session, with the equine welfare charity venue able to provide a high number of colts for castration work. Nerve blocks and regional anaesthesia for other common procedures will also be covered on cadavers.
For further information on BEVA’s new CPD courses visit www.beva.org.uk/cpd
Eurovet Animal Health has announced that it is bringing a veterinary licensed vitamin K1 (phytomenadione) injectable preparation to the UK.
Eurovet says the new preparation, available from the wholesalers by Monday at the latest, will ensure that the previous supply problems of vitamin K1, will be overcome.
According to the company, the intravenous route is the only route to ensure a 100% bioavailability of vitamin K1 almost immediately and in a crisis situation is the best route of treatment. During anticoagulant poisoning, the coagulation factors are present in the body but are not functional. The faster vitamin K1 enters the blood flow, the quicker the coagulation function is restored.
Ruth Vernon, Technical Services Manager for Eurovet said: "We also plan to bring veterinary licenced vitamin K1 tablets to the UK market later in the year, allowing them to be ordered direct from veterinary wholesalers. The future continuity of supply represents a significant improvement on the current situation."
Anticoagulant rodenticide poisoning is the second most common query received by the VPIS. Alexander Campbell, Head of Service at VPIS, said: "The Veterinary Poisons Information Service receives well over 1000 telephone enquiries per annum from UK veterinary professionals seeking advice on how to manage potential and accidental exposures to anticoagulant rodenticides in a variety of animals - mainly pet dogs. Whilst most cases require basic assessment, first-aid and precautionary laboratory tests, an inevitable few develop serious intoxication and need long-term treatment. Vitamin K1 is a mainstay of therapy in these instances, and the availability of licensed veterinary-specific products in the UK is a major advance. Previously, preparations licensed for human use were often the only option when these could be sourced. Anything that ensures ready supply and facilitates speed of therapy for severe cases has to be welcomed."
There are over 500 anticoagulant rodent killing preparations available across Europe. They are available ready to use, as coated cereals, bait blocks, tracking powders, semolina formats or concentrates (which are reserved for professional use). Following cut backs in local council spending on pest control, the National Pest Technicians Association identified in a recent survey* that there is a 'worrying increase in poorly-managed DIY rodent control'.
*The NPTA National Rodent Survey 2009/2010
The study was part of a research project called VetCompass, through which the RVC, in collaboration with Vets Now, collects anonymised clinical information on over 6 million companion animals under veterinary care in the UK.
The study investigated bitches presented with difficulty giving birth (dystocia) from among almost 20,000 bitches attending 50 Vets Now surgeries. Researchers found that out of 20,000 bitches receiving emergency veterinary care, 3.7 per cent of these were treated because of difficulties encountered giving birth.
The most commonly affected breeds were the French Bulldog (15.9 times more likely), Boston Terrier (12.9 times more likely), Chihuahua (10.4 times more likely) and Pug (11.3 times more likely).
Dr Dan O’Neill, a companion animal epidemiologist within the VetCompass Programme, said: "Giving birth in dogs is not always a benign process and our research shows this risk is especially exacerbated in some common brachycephalic and toy breeds. Prospective owners should bear these welfare costs for high risk breeds in mind when choosing their new puppy."
Caroline Kisko, Kennel Club Secretary, said: 'VetCompass' research will not only enable dog breeders to make responsible breeding choices to improve the health of these dogs, it will help to highlight what puppy buyers need to be looking out for if they are intent on owning one of these breeds. If people are choosing a breed simply for its looks and are not going to a reputable breeder, they are likely to face high vet costs and a lifetime of heartache."
This study builds on previous 'purchasing' research by the RVC which found that appearance is the number one reason why owners purchase flat-faced breeds, even though their large, round, wide-set eyes, and flat rounded faces are linked with a variety of inherited diseases.
Dr Rowena Packer, lead author of the study and Research Fellow at RVC, said: "Potential puppy buyers attracted to the appearance of these breeds should seriously consider whether they are emotionally and financially prepared to take on a breed with high risks of health complications, and consider whether alternative, lower-risk breeds would better fit their lifestyle."
For the research1, 190 faecal samples were collected from dogs in 140 households (114 samples from raw fed dogs and 76 from non-raw fed dogs).
Salmonella species was detected in 4% of the samples (all raw fed) and antimicrobial-resistant E. coli was detected in 40% of all dogs, but in 62% of raw fed dogs.
The authors say that statistical analysis confirmed that this represented a significantly higher prevalence of AMR E. coli, including multidrug resistance and third generation cephalosporin resistance, and Salmonella species in dogs fed raw compared to non-raw meat diets.
The authors concluded that strategies should be implemented to increase the awareness of the risks of feeding raw meat diets to dogs, to reduce any potential risk to owners, their families, and their pets.
Nicola Di Girolamo, Editor of JSAP says: “In this study, an association between raw meat diets in dogs and faecal carriage of potentially dangerous enteric bacteria has been observed.
"Readers should keep in mind that cross-sectional studies such as this one lay the basis for additional research more suited to prove causality.”
Reference
The awards, comprising academic book vouchers, were presented at the University’s RCVS ceremony after graduation earlier this month.
Jamie Rahman BVSc won the award for the most engaged veterinary student on EMS placement. Feedback about his placement included: 'Exceptional attitude'. 'Contributed actively to good clinical discussion'. 'Intelligent and engaging’. 'Shows true dedication to learning as much as he can whilst in practice, trying to spend as much time with the different specialists as possible'.
Meanwhile, Cheviot Vets in Alnwick won the students' award for outstanding clinical EMS placement 2019. Comments received from students included: ‘I would not be nearly as prepared and ready for practice without the support and training of the team at Cheviot Vets.’ ‘They invested an incredible amount of time into helping me develop my husbandry knowledge and skills.’ ‘Really supportive manner and encouraged me to develop my skills.’
Sarah Heming, Director of Public Affairs and Customer Relations at Zoetis said: "Zoetis has a high focus on supporting the professional advancement of the veterinary profession. We are proud sponsors of the EMS Recognition Awards for Bristol University alongside other initiatives such as the Young Vet of the Year Awards in partnership with the British Veterinary Association.
"The initial stages of a veterinary career are pivotal so helping winning individuals to invest in academic or professional resources to support their continued development in practice can be very beneficial. We would also like to formally thank the winning practices for their invaluable commitment and support."
The Stablelab hand-held reader detects and quantifies the biomarker Serum Amyloid A (SAA), an acute phase protein produced by the liver that increases rapidly and dramatically in response to inflammation.
Zoetis says that by measuring SAA, vets can assess the severity of an infection more quickly, often before clinical symptoms start, and are able to monitor the horse’s response over the course of treatment.1
Zoetis vet Wendy Talbot said: “Zoetis is committed to providing vets and horse owners with the most effective health products to better predict, prevent, detect and treat equine disease.
“The Stablelab test kit enables convenient, off-site testing for quick and accurate detection of a reliable indicator of infection in horses.
“Point-of-care testing is one of the fastest-growing areas of diagnostics and this test is rapidly becoming a standard of care in equine practice. SAA testing will help vets to quickly determine an appropriate course of intervention, positively impacting case outcomes.”
For more information, visit: www.stablelab.com. To place an order, contact your Zoetis Account Manager or the Zoetis Technical Team on customersupportUK@zoetis.com or 0845 300 9084 (option 3).
Creature Comforts will be using the cash both to open the clinics and build a proprietary app which will give owners seamless 24/7 access to veterinary care, whilst allowing vets to work more flexibly and more often from home.
VetSurgeon.org caught up with Russell Welsh (pictured), co-founder of the new business alongside Daniel Attia.
Russell said: "During the pandemic, there was a recognition that employers needed to do more to attract and retain veterinary staff, and so there has been a move towards more flexible working and better employment packages.
"The problem is that we then saw a massive increase in the number of pets, and the profession is struggling to meet demand.
"On top of that, the corporatisation of the profession has meant that both staff and owners often feel less connected with each other.
"We think the answer lies in independent practices making better use of technology to reduce the workload on veterinary staff whilst creating a better, seamless, more personal experience for pet owners.
"There are of course companies offering online consultations, but they tend to be stand alone services, or belong to corporate groups.
"What we're doing differently is developing our own system so that we don't lose control of any stage in the client journey and can make sure the quality of care, after care and service is consistently high.
"We'll also be putting together a share option scheme, so our employees will really feel a proper sense of ownership."
https://www.creaturecomforts.co.uk
RCVS CEO Lizzie Lockett said: "I am so proud of our performance in the Great Place to Work Awards and the efforts of everyone at the College, and especially our HR team, who have been tirelessly and creatively striving to make the College a wonderful place to work.
"Consistently being placed in the top 50 Great Places to Work is also a testament to the sustained hard work all of our employees and the important part they play in creating a supportive, interesting and good-humoured workplace.
"We are a service-led organisation and we want to make sure that we give our best to the veterinary professions and the general public. If our team enjoys the work, and the workplace, that will improve the service we are able to offer and, ultimately, benefit animal health and welfare."
The consultation, which was held by the College early in 2017, asked for the views of veterinary surgeons and nurses, animal owners, and stakeholders on the use of telemedicine in veterinary clinical practice.
The consultation was designed to help identify potential risks associated with telemedicine, identify areas where it may help address the needs of both clinicians and the public, and support the potential development of new professional standards and guidance.
The online survey of veterinary professionals received 1,230 responses, while the public consultation received 229 responses and the survey of organisations/stakeholders received eight responses.
The headline question asked of veterinary professionals was whether RCVS 'supporting guidance to the Code of Professional Conduct' should be amended to allow remote examination to take the place of physical examination in certain circumstances. 41% said 'Yes', 40% said 'No' and 18% were unsure.
Veterinary professionals and organisations were then asked a series of questions in order to establish how they rated the risk associated with telemedicine according to activity type, practice type, clinical sign or syndrome, mode of technology, and familiarity with client, animal or environment.
Unsurprisingly perhaps, the majority felt that providing just general advice presented a low risk. At the other end of the scale, most felt that the use of telemedicine to diagnose disease or injury would be either 'high risk', or 'not appropriate at all'.
Likewise, the majority said the risks would be low or medium where the client and environment were known and the animal seen before, for the same problem. By contrast, the majority said telemedicine would be either 'high risk' or 'not appropriate at all' when the client, animal and environment were all unknown.
When asked whether the current definition of 'under care' should be extended to allow veterinary surgeons to prescribe veterinary medicines where there has been no physical examination of the animal, 69% said 'No', 16% said 'Yes' and 15% were unsure.
However, when asked whether certain types of veterinary medicines should be able to be prescribed without a physical examination of the animal, the majority of respondents to the professional survey (52%) were in favour.
The results of the consultation were first considered at a special meeting of the Standards Committee in August 2017, where it was noted how the consultation had revealed significant confusion around current supporting guidance to the RCVS Code of Professional Conduct and that, at a minimum, clarification as to what was currently permissible was needed.
The Committee determined a key issue going forward was whether to change the Supporting Guidance to the RCVS Code of Professional Conduct regarding 'under care' to allow veterinary surgeons to prescribe POM-V medicines based on telemedicine alone.
Given the complex nature of the issues and the wide-ranging implications, the Standards Committee presented a range of options for amending RCVS Guidance to RCVS Council at its meeting in November 2017. After discussion, Council asked the Standards Committee to continue their review and to present more detailed proposals to Council regarding the future of telemedicine in clinical veterinary practice.
Anthony Roberts, RCVS Director of Leadership and Innovation, said: "We would like to thank all those who took the time to respond to the consultation – although Council has not yet made any firm decisions, we felt it would be useful to share our research so far.
"The use of telemedicine is growing rapidly in human healthcare and it is only right the RCVS assesses the opportunities it could bring to improve access to veterinary services. It is critical, however, that we understand the issues it presents 'at the coal face' and consider all the available evidence before making any changes to our Guidance. The RCVS should ensure its regulatory framework fosters innovation and maximises the opportunities to improve the quality, efficacy and accessibility of veterinary services, whilst at the same time protecting animal health and welfare."
The Standards Committee will meet again in April 2018 to take further evidence and develop proposals to take the issue forward.
Meanwhile, the full summary is available on the College’s website: www.rcvs.org.uk/telemeds-summary/.
Available for download now, the MobiVet Veterinary Formulary App is designed to make drug calculations and prescribing faster, easier and safer. It contains dose rate and interval data for over 250 drugs commonly used in small animal practice.
Searchable by drug name or trade names, with species-specific dosing information, the app calculates doses based on the patient type, weight, or body surface area as appropriate. MobiVet also provides a checklist of known relevant drug interactions for each medication, to prevent prescribing errors.
Stuart says an iOS version is in production.
To download the Android version, visit: https://play.google.com/store/apps/details?id=com.project.user.drug_formulary&hl=en
Working in collaboration with researchers at University of Texas, Southwestern (UTSW) Medical Center, the team has succeeded in using gene editing techniques on dogs to restore the expression of the dystrophin protein that is absent in DMD patients’ muscles to levels that could be life changing.
DMD is the most common, fatal, genetic disease that affects children. The same disorder also occurs in many dog breeds. It is caused by mutations in the gene that encodes dystrophin, a crucial protein that helps protect muscle fibres and the heart when they contract. Patients with the disease produce effectively no dystrophin protein, so their muscles and heart become damaged during contraction, leading to inability to walk, skeletal deformities, breathing problems and heart failure. Patients with DMD have a life expectancy that does not go far beyond their twenties.
Researchers say that this preliminary research, published in Science, demonstrates an approach that could lead to an effective, in principle one-time treatment for DMD for the most common genetic mutations affecting human patients. Through a single intravenous injection, researchers have been able to modify the dystrophin gene in many muscles of the body, including the heart, with the result that some muscles now had almost the normal amounts of dystrophin protein.
The team, led by Eric Olson, Ph.D., professor and chair of the Department of Molecular Biology at UTSW Medical Center and founder and chief science advisor of Exonics Therapeutics, and Richard Piercy, Ph.D., MRCVS, Professor of Comparative Neuromuscular Disease at the RVC, identified a naturally-occurring mutation in the dystrophin gene in a dog brought to the RVC’s Small Animal Referral Hospital.
Working now with relatives of this first dog, the combined group has used a technique called ‘SingleCut CRISPR gene editing’, where the researchers target a specific region of the subject’s own DNA. Harmless viruses encoding the gene-editing protein CRISPR/Cas9 were used to express the enzyme in muscle to cut the dogs’ own DNA at a precise location in the dystrophin gene through use of a molecular guide. The body’s own processes then repair the cut, which results in removing the negative effects of the existing mutation.
The researchers have demonstrated that dogs treated in this way had restored ability to produce large amounts of the dystrophin protein in their muscles and heart, and in the dog with the highest dose, cardiac muscles were found to have restored dystrophin protein to up to 92% of normal amounts after the single treatment.
The team believes this is the first time that this form of gene editing therapy has been conducted after birth in an animal larger than a rodent. With further longer-term research, efficacy and safety testing, it is hoped that this breakthrough will have human application. This treatment may be a significant step toward developing a gene editing therapy to repair genetic mutations for DMD, as well as a range of diseases caused by genetic mutations.
Richard Piercy, Professor of Comparative Neuromuscular Disease at the RVC, said: "Researchers have been looking for an effective and durable treatment for Duchenne muscular dystrophy for many years. This SingleCut gene editing approach, pioneered by Dr. Eric Olson’s group, has the potential to be a one-time treatment that could restore dystrophin protein. It is hugely exciting that through a single intravenous injection we’ve been able successfully to modify the dogs’ own DNA so they start generating dystrophin protein again. There is more work to be done, but with this exciting breakthrough, we feel we are a significant step closer to finding an effective treatment.
"A great many genetic diseases affect humans, dogs and other species - many, like DMD - with tragic consequences and this form of gene editing treatment might well be applicable in many of them. We’re hopeful that we’re paving the way for future research into treating some of the most serious genetic conditions that affect us today."
MsRCVS Sean Cleary and Richard Thomas, and accountant Jane Platt have opened their first practice, Burford Lane Vets in Cheshire, and now plan to open 10 more practices over the next five years, two in Spring 2022
Burford Lane Vets is headed up by Pieter De Villiers MRCVS, who has become an equity owner, supported by a team of nine vets, nurses and receptionists.
Sean said: “Our vets benefit from our many years of clinical, financial, human resources and procurement experience and have the opportunity to add the finishing touches to a state-of-the-art practice, where no expense has been spared on the fit out and equipment.
"Everything from finding a property, negotiating the lease, fitting out the practice and health and safety is taken care of.
"It means our equity partners can enjoy being fantastic vets and reap the financial rewards that brings, and we are here to support the practice and take care of all the administration, procurement, marketing and everything else that goes into running a successful business."
Sean added: “We have benefited from the shift in the industry that saw veterinary groups acquired by large corporate businesses.
"However, this has inadvertently made it difficult for the next generation of vets to follow the traditional route of buying into a practice as they progress from a junior role to partner, as corporate interest has pushed the values of practices to unaffordable levels for most vets.
"We want to bridge that gap and give a leg up to vets who want to be masters of their own destinies, without the difficulty of starting from scratch or having to find a huge initial investment.”
Sean says he thinks there are a great many vets who would like to launch their own practice.
However, starting from scratch is fraught with risk, expense, and complexity.
Sean added: “Our innovative model helps great vets set up in business as leaders of their own practice and our unique offering is already attracting interest from high-calibre individuals.
"We would encourage any colleagues out there who feel they would like to join us in our new venture to get in touch via our website.”
Sean concluded: “The business acumen we have built up over our many years of working in the industry enables us to provide practical support, mentorship and guidance for vets through every step of the process, and that’s something we’re passionate about.
"The directors will be working across all practices to provide support whenever it’s needed. We are in it for the long haul, not just the initial set up stage, and we will become a part of every practice that opens.
“We take a real pride in being the solution to fix the broken practice ownership model and North Star Vets will empower ambitious vets to enjoy a better and more successful future, which in turn will translate into the standard of care our clients enjoy.”
Protexin has announced that preliminary data from a clinical trial supports the use of Denamarin® to protect against lomustine (CCNU)-induced hepatotoxicity in dogs.
The study is being performed at the University of California-Davis, Veterinary Medical Teaching Hospital, and the initial results were recently presented at the American College of Veterinary Internal Medicine (ACVIM) Annual Forum. Marketed in the UK by Protexin, Denamarin is the combination of S-adenosylmethionine (SAMe) and silybin.
According to the company, most dogs treated with the chemotherapeutic agent CCNU experience liver enzyme elevation. Elevation of certain liver enzymes such as alanine transferase (ALT) is a key indicator of liver trauma; significant enzyme elevation may lead to a discontinuation, delay, or reduction in chemotherapy. The ongoing clinical trial was designed to evaluate Denamarin as a hepatoprotectant in dogs diagnosed with neoplasia that are undergoing CCNU therapy.
The trial consists of two groups of randomly assigned dogs. Dogs in Group 1 receive Denamarin beginning at the start of CCNU therapy. Group 2 dogs do not receive Denamarin unless they develop a Grade IV hepatotoxicity.
Results of a planned interim analysis completed on the first 30 dogs enrolled revealed that starting Denamarin when CCNU therapy was instituted (Group 1 dogs) appeared to provide hepatoprotection. While the mean post-therapy ALT elevation for Group 1 was 119 IU/L (p=0.1), for Group 2 dogs, the post-therapy ALT level was 815 IU/L (p=0.046). Chemotherapy was altered due to elevated liver enzymes in three Group 2 dogs but only one dog in Group 1.
Janine Barlow, Technical Manager at Protexin said: "We are extremely pleased by the initial findings of this research. The use of Denamarin with chemotherapy looks to help protect liver function allowing for successful completion of therapy and hopefully a longer, happier life for the pet. We look forward to the results of the full study."
Protexin says the SAMe and silybin in Denamarin support and maintain hepatic function by mechanisms including increasing levels of glutathione, the liver's main detoxifying agent; promoting protein synthesis; and stimulating bile flow. Denamarin is useful as part of a polymodal approach to the management of liver health.
Denamarin is available for both dogs and cats in an enteric-coated tablet.
Running in July, the campaign aims to raise awareness of hyperthyroidism in cats and hypothyroidism in dogs, educate pet owners to spot the symptoms and thereby encourage early diagnosis.
MSD Animal Health says it hopes the campaign will increase the number of pets being taken to their veterinary practice for diagnosis, and increase both return visits and treatment compliance.
Practices supporting Pet Thyroid Month will be supplied with resources to help them educate pet owners about the two conditions.
Caroline Darouj, product manager at MSD Animal Health, said: "Although hyperthyroidism in cats and hypothyroidism in dogs are well known conditions and diagnosis is generally straightforward, a large number of vets in Europe state that both disorders are under-diagnosed, due to the fact that pet owners don’t recognise the signs.
"We wanted to launch our Thyroid Month campaign to encourage pet owners to spot the early symptoms of thyroid issues in their pets and seek advice from their veterinary practices.
"Our aim is also to benefit and educate vets and vet nurses with regard to the use of Leventa and Vidalta in treating these manageable conditions in both dogs and cats."
To find out more about Pet Thyroid Month, visit www.vidalta.co.uk
The RCVS Disciplinary Committee has removed a veterinary surgeon formerly working in Lincolnshire from the Register, after finding him guilty of serious professional misconduct for drink-driving related convictions, failing to inform his employer of these convictions, and driving whilst disqualified.
Jaroslaw Slominski, a former employer of Grants Veterinary Services plc, chose not to attend the three-day hearing. The Committee considered whether to proceed with the case, using criteria identified by the Court of Appeal in R v Jones (Anthony) in 2002 and confirmed by the House of Lords. It concluded it was in the interests of justice that the hearing should go ahead.
The charges related to two convictions Mr Slominski received on 17 March 2010 at Lincoln Magistrates Court: failure to provide a specimen of breath for analysis and driving without due care and attention (after his vehicle collided head-on with another car). Mr Slominski failed to inform his employers of these convictions, as he was contractually obliged to do, and that he was now disqualified from driving.
Having heard evidence from Mr Slominski's line manager, the Committee also found that he had driven his employer's vehicle whilst disqualified, although it could not be sure that he had done so on all the occasions alleged. Therefore, the Committee did not go on to consider an alternative part of the charge - that Mr Slominski had dishonestly claimed money from his employer by falsely submitting expenses claims.
Disciplinary Committee Chairman Prof Peter Lees said: "The combination of factors in this case, namely, the serious nature of his conviction in failing to provide a specimen of breath, his subsequent premeditated conduct in not informing his employers and driving whilst disqualified should be treated by the profession very seriously. The Committee has concluded that the combination of the conviction and the conduct is incompatible with Mr Slominski practising as a veterinary surgeon."
The Committee directed that Mr Slominski's name be removed from the Register.
Idexx has launched Pet Resist (www.petresist.com), an online map of the levels of antibiotic resistance recorded in cats and dogs by the company over the past five years.
The map displays geographical variations in resistance to the top 10 antibiotics used in cats and dogs.
Simon Wootton, UK CAG Marketing Manager from Idexx said: "The ability to select the most appropriate antibiotic prior to testing may increase the effectiveness of treatments and reduce the number of return visits. We believe that this new service will also help prolong the effective life of existing antibiotics at a time when there is considerable pressure on the profession to reduce their use."
Pet Resist shows levels of resistance overlaid on an interactive UK map down to individual postcode areas. You enter the postcode, the antibiotic (amoxicillin, ampicillin, cefaliexn, etc) and the suspected organism (E coli, S aureus, etc), after which you'll be able to see the level of resistance based on historical data from the past five years, and use this to help choose appropriate therapies.
Simon added: "We have used results of MIC tests on over 200,000 samples submitted to Idexx to develop the database upon which the resistance levels are based. The data will be continually updated as we receive more samples at our Wetherby laboratory, further increasing the accuracy and value of the service to vets and their clients."
Dilaterol is an oral syrup containing 25 mgs/ml clenbuterol hydrochloride, indicated to treat respiratory disease in horses. It causes intense bronchodilation, inhibits histamine release and increases ciliary mucous clearance. It can be used as a frontline or adjuvant therapy.
Dilaterol is administered via food and comes in a 355 ml bottle with a pump dispenser for easy and accurate dosing.
Emma Jennings, Equine Brand Manager at Dechra said: “We are very pleased to have added Dilaterol to our comprehensive range of equine therapies as it is an established and effective treatment for bronchial conditions.
"It is particularly useful in cases of respiratory allergy, bronchospasm and equine asthma and is already regarded as a valuable tool for veterinary professionals."
Dilaterol will be available to order through wholesalers. For more information, visit www.dechra.co.uk.
The company says that despite the development of alternatives to natural bone grafting, such as allografts and synthetic products, autologous bone graft is still considered the standard. However, it has a number of disadvantages, such as donor site morbidities and lameness, limited availability of graft volume (particularly in small size pets) and additional surgical time.
Biocera-Vet is a new bone substitute indicated in surgical procedures where bone grafting is necessary, such as arthrodesis, complex fractures, corrective osteotomy used in correction of limb deformities or as add-on to Tibial Tuberosity Advancement (TTA).
Biocera-Vet is an injectable synthetic self-hardening calcium-phosphate cement combining osteo-inductive, osteo-conductive and osteo-integrative properties designed to support a fast and strong consolidation.
TheraVet says Biocera-Vet also presents an excellent safety profile thanks to its biocompatibility, reduced comorbidities and superior ergonomics which save a significant amount of surgical time.
Dr Olivier Stiévenart, an orthopaedic veterinary surgeon at Surgivet in Belgium said: "Using Biocera-Vet has enabled us to optimise our patient care considerably, by reducing the operating time by at least 30 minutes. The use of an efficient and rapid bone substitute represents a real progress in terms of both operations and the animal’s quality of life".
Julie Schurgers, Chief Commercial Officer of TheraVet, said: "Biocera-Vet is a unique product on the veterinary bone substitute market, combining outstanding bone consolidation properties with an excellent safety profile and superior ergonomics. We are very excited today to announce its commercialisation on the market and are convinced that this innovative product will significantly improve the daily practices of veterinarians, for the well-being of patients and their owners."
The product is now available in Belgium, and will be rolled out in France and the Netherlands shortly, with the rest of Europe following later in 2021 / 2022.
For more information, visit: https://www.thera.vet/en/biocera-vet
The strange phenomenon was spotted by Veterinary Vision's clinical director Chris Dixon when he examined Dachshund called Margo, which had been referred for the treatment of a corneal ulcer and fungal infection.
Chris said: “I was assessing Margo’s eye and was very surprised to see a face smiling back at me.
"It perhaps doesn't bear quite the same resemblance as the Turin Shroud. Still, I've never seen anything like it before.
"The good news is that it does not appear to have affected her vision at all.”
Apparently the smiling face is still there, even after Chris performed a corneal graft.
Chris added: "I think we can safely say that Margo is a very happy dog, both inside and out!"
Ceva Animal Health has launched Hepatosyl Plus, a development of the liver support supplement for cats and dogs.
Hepatosyl Plus contains the same ingredients as the original product but now also includes Silybin. According to the company, Silybin is the most active isomer of Silybum marianum (milk thistle) which acts as an antioxidant by increasing cellular superoxide dismutase. It joins S-adenosylmethionine (SAMe) and Vitamin E to create a triple antioxidant approach to liver support, helping to neutralise free radicals within the liver. Ceva also says Hepatosyl Plus is the only liver supplement to contain Vitamin K, which is needed by the liver for the production of clotting factors II, VII, IX and X, making it ideally suited for pre- and post-anaesthetic liver support.
Hepatosyl Plus is available in 50mg, 100mg and 200mg sprinkle capsules. For anaesthetic support, Hepatosyl Plus should be administered for one week prior to and following anaesthesia. For long-term use, the capsules should be given once daily for 2-3 months and then reduced to every other day for ongoing maintenance.
For further information, please contact your local CEVA Animal Health territory manager or call 01494 781510.
During the webinar, which took place earlier this month, senior officers and staff from the College explained the new guidance, what it will mean for the profession, and answered questions submitted by delegates.
The webinar was chaired by RCVS President Dr Melissa Donald MRCVS with a panel comprising Standards Committee Chair Linda Belton MRCVS, RCVS Registrar Eleanor Ferguson, and RCVS Head of Standards Gemma Kingswell.
The webinar included an overview of the main changes, the considerations to take into account when prescribing POM-Vs remotely, the circumstances under which POM-Vs cannot be prescribed remotely, the prescription of antibiotics, antifungals, antiparasitics and antivirals, and how the guidance will be enforced.
Eleanor Ferguson, RCVS Registrar, said: “We have also now published a range of practice-based scenarios to help explain how the new guidance should be followed in various circumstances, and in relation to different species.
"These scenarios cover a variety of different situations, including how the guidance applies to two or more practices with mutual clients, consultancy services and the prescription of long-term controlled drugs.”
A second webinar will be held on Monday 17th July, with priority for those who wanted to attend the June webinar but were not able to do because it was over-subscribed.
www.rcvs.org.uk/undercare
Zoetis has announced the launch of Zulvac SBV, a new Schmallenberg vaccine licensed for use in cattle and sheep in two doses at a three week interval, the second at least two weeks before mating.
Zulvac SBV is licensed for use in cattle and sheep in two doses at a three week interval, the second at least two weeks before mating.
Duration of immunity is six months in cattle and seven in sheep. At the recommended vaccination timing, this covers the window of susceptibility during pregnancy; in sheep from day 28 to 56, and days 70 to 150 in cattle. Animals infected during these periods are at risk of malformed offspring and subsequent stillbirth.
The company says vaccination combined with insecticidal measures to control the midge vector remains the most effective way of protecting the population1 and ensuring a more unified level of immunity.
Zoetis vet Carolyn Hogan said: "Although SBV is now considered to be an enzootic pathogen in England and Wales, there is plenty of evidence that seroprevalence at farm level – particularly on sheep farms - varies. As immunity wanes, the proportion of herds and flocks naïve to SBV and at risk via introduction of naïve replacements increases. So the risk of reinfection in assumed enzootic areas is potentially underestimated2.
"Culicoides midges, the SBV vector, are widespread in Europe and move easily between farms and regions, allowing rapid spread of infection."
Carolyn says that whilst there have been no confirmed diagnoses of congenital abnormalities in calves or lambs from APHA in 2014 or 2015, unconfirmed anecdotal cases have been reported.
"We do not know whether our ruminant population is immune or susceptible and neither do we know if another SBV challenge will appear. Vaccination remains the most effective way of ensuring valuable livestock are protected."
Supplies are available immediately.
References